New Antimicrobial Agents for Children.
- Author:
Byung Wook EUN
1
Author Information
1. Department of Pediatrics, Graduate School of Medicine Gachon University of Medicine and Science, Incheon, Korea. acet0125@gilhospital.com
- Publication Type:Review ; Clinical Trial
- Keywords:
Anti-Bacterial Agents;
Antiviral Agents;
Child
- MeSH:
Acetamides;
Anti-Bacterial Agents;
Anti-Infective Agents;
Antiviral Agents;
Carbapenems;
Child;
Daptomycin;
Drug Resistance, Multiple;
Hepacivirus;
Humans;
Methicillin-Resistant Staphylococcus aureus;
Otitis Media;
Oxazolidinones;
Vancomycin;
Virginiamycin;
Linezolid
- From:Korean Journal of Pediatric Infectious Diseases
2009;16(1):6-12
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
There are relatively few novel antimicrobial agents despite the dramatic increase in antimicrobial resistance and multiple drug resistance of clinical isolates worldwide. Vancomycin is still the most widely used antibiotic for treating resistant Gram-positive coccal infections in children, especially for methicillin-resistant Staphylococcus aureus. For children with Gram-positive coccal infections where vancomycin is not effective or older therapeutic agents cannot be tolerated, linezolid, quinupristin-dalfopristin or daptomycin may be useful in the appropriate clinical setting. For Gram-negative infections, new carbapenems await clinical application. Tebipenem pivoxil is a novel oral carbapenem undergoing clinical trials for acute otitis media in pediatric patients. Antiviral drug development is now progressing at the pace of antibiotic development 30 years ago. Newer antiviral agents used for the treatment of herpes viruses and hepatitis C virus infections in children are included in this review.
